<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800928</url>
  </required_header>
  <id_info>
    <org_study_id>1602017291</org_study_id>
    <secondary_id>P50DA033945</secondary_id>
    <nct_id>NCT02800928</nct_id>
  </id_info>
  <brief_title>Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?</brief_title>
  <official_title>Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human
      Laboratory Model of Stress-precipitated Smoking Behavior.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in subjects who are heavy cigarette smokers currently not seeking
      treatment for tobacco use disorder.

      The study is a crossover design study (within-subject analysis), which allows for subjects to
      be their own control.

      Each period of the crossover consists of a 7-day out-patient treatment period followed by a
      single out-patient testing day on Day 8. Subjects will participate in a laboratory session
      following the McKee Stress-Smoking Lapse Test. Upon completion, subjects will undergo a 7 day
      washout period followed by the second period of the crossover design and a 7-day follow-up
      visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">January 2, 2018</completion_date>
  <primary_completion_date type="Actual">January 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Latency</measure>
    <time_frame>50 min</time_frame>
    <description>Latency (in minutes and seconds) to time of first cigarette smoking during the delay period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Cigarettes Smoked</measure>
    <time_frame>60 min</time_frame>
    <description>Number of cigarettes smoked during the self administration period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>CERC-501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily, 10mg daily, 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally daily, 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CERC-501</intervention_name>
    <description>CERC-501</description>
    <arm_group_label>CERC-501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Provides written informed consent and agrees to complete required clinic visits

          2. Male or female 21 to 60 years of age inclusive

          3. Body mass index (BMI) 18.5 to 40 kg/m2 inclusive

          4. Smokes at least 10 cigarettes per day on average for the past 6 months

          5. Fagerstrom score ≥3 at screening

          6. Currently not seeking smoking cessation therapy

          7. Urine dip test for cotinine concentration &gt;150 ng/mL

          8. In otherwise good general health without any unstable medical conditions (as
             determined by medical history, medication history, physical examination, 10- or 12
             lead ECG, vital signs, and clinical laboratory testing)

          9. Able to read, write, and speak English

         10. Females must be either:

               1. Post-menopausal (amenorrhea for at least 12 consecutive months), surgically
                  sterile -or-

               2. Women of childbearing potential (WOCBP) must meet the criteria below:

             i. Uses an acceptable double-barrier method of contraception as determined by the
             Investigator -and- ii. Is not lactating, has a negative serum beta human chorionic
             gonadotropin pregnancy test at screening and a negative urine pregnancy test prior to
             dosing on Days 1 and 8 of each treatment period.

         11. Male subjects must agree to use a condom if partner is of childbearing potential

        Exclusion Criteria

          1. Have used tobacco or other nicotine containing products other than cigarettes (e.g.,
             nicotine patches, pipe, cigars, snuff, chewing tobacco or e-cigarettes) within the
             past 30 days

          2. Any substance use disorder other than nicotine or caffeine as assessed by the
             Structured Clinical Interview-IV Axis I Disorders (SCID) for Diagnostic and
             Statistical Manual of Mental Disorders (DSM)

          3. Current neurological conditions that interfere with study conduct, assessment or
             treatment in any significant fashion

          4. Any lifetime history of bipolar I, II; schizophrenia or any other psychotic disorders;
             personality disorders, impulse control disorders as assessed by the SCID-IV

          5. Current psychiatric conditions that interfere with study conduct, assessment, or
             treatment in any significant fashion, such as major depressive disorder (MDD), eating
             disorders, post-traumatic stress disorder, etc. We will screen for worsening of
             symptoms of depression and/or suicidality at each medication appointment and lab
             sessions by having participants complete the Beck Depression Inventory (BDI) and the
             Columbia-Suicide Severity Rating Scale (C-SSRS). If there is a worsening of symptoms
             of depression and/or suicidality, the participants will speak a licensed psychologist
             for evaluation.

          6. Recent active or past history of gastric disease such as peptic ulcer disease,
             gastritis, upper gastrointestinal bleeding, or any gastrointestinal malignancy or
             precancerous condition

          7. Active, comorbid disease that might limit the ability of the subject to participate in
             the study as determined by the Study MD (i.e., poorly controlled diabetes mellitus,
             congestive heart failure, etc.)

          8. Clinically significant clinical laboratory test taken during screening

          9. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times
             the upper limit of normal (ULN)

         10. Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C positive as determined
             by serology testing at Screening

         11. Positive ethanol breath test at screening or prior to dosing on Days 1 and 8 of each
             treatment period

         12. Positive urine drug test at screening or and/or prior to dosing on Days 1 and 8 of
             each treatment period except for cannabis

         13. History of severe allergies or multiple adverse drug reactions

         14. Known hypersensitivity to CERC-501

         15. Current use of a proton pump inhibitor or histamine 2 blocker

         16. Use of any investigational medication within 2 months prior to the start of this study
             or scheduled to receive an investigational drug other than the study drug during the
             course of this study

         17. Current use of any psychoactive medications including: antipsychotics,
             benzodiazepines, mood stabilizers, selective serotonin reuptake inhibitor/serotonin
             norepinephrine reuptake inhibitor (SSRI/SNRI) or other antidepressants mood
             stabilizers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <results_first_submitted>March 4, 2019</results_first_submitted>
  <results_first_submitted_qc>July 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sherry McKee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02800928/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a cross-over design. Medication arms are within-subject.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment First</title>
          <description>Administered orally once daily, 10mg daily, 8 days
CERC-501: CERC-501
7 day wash-out
Administered orally once daily, placebo, 8 days
Order of placebo/CERC-501 counterbalanced</description>
        </group>
        <group group_id="P2">
          <title>Placebo First</title>
          <description>Administered orally once daily, placebo, 8 days FIRST
7 day wash-out
Administered orally once daily, CERC-501: CERC-501 10mg daily, 8 days SECOND</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Administered orally once daily, 10mg daily, 8 days
CERC-501: CERC-501
7 day wash-out
Administered orally once daily, placebo
Order of placebo/CERC-501 counterbalanced</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.18" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.24" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Latency</title>
        <description>Latency (in minutes and seconds) to time of first cigarette smoking during the delay period</description>
        <time_frame>50 min</time_frame>
        <population>13 subjects completed study (i.e., completed both CERC-501 and Placebo periods in this cross over design).</population>
        <group_list>
          <group group_id="O1">
            <title>CERC-501</title>
            <description>Administered orally once daily, 10mg daily, 8 days
CERC-501: CERC-501</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Administered orally daily, 8 days
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Latency</title>
          <description>Latency (in minutes and seconds) to time of first cigarette smoking during the delay period</description>
          <population>13 subjects completed study (i.e., completed both CERC-501 and Placebo periods in this cross over design).</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.56" spread="6.40"/>
                    <measurement group_id="O2" value="26.64" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Cigarettes Smoked</title>
        <description>Number of cigarettes smoked during the self administration period</description>
        <time_frame>60 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CERC-501</title>
            <description>Administered orally once daily, 10mg daily, 8 days
CERC-501: CERC-501</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Administered orally daily, 8 days
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cigarettes Smoked</title>
          <description>Number of cigarettes smoked during the self administration period</description>
          <units>number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.28"/>
                    <measurement group_id="O2" value="1.92" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days</time_frame>
      <desc>SAFTEE assessment.
In total 16 subjects were exposed to CERC-501 and are included in adverse event analysis. In total 15 subjects were exposed to placebo and are included in the adverse event analysis. This is a cross-over design.</desc>
      <group_list>
        <group group_id="E1">
          <title>CERC-501</title>
          <description>Administered orally once daily, 10mg daily, 8 days
CERC-501: CERC-501</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Administered orally daily, 8 days
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sherry McKee PhD</name_or_title>
      <organization>Yale School of Medicine</organization>
      <phone>203-737-3529</phone>
      <email>sherry.mckee@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

